Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aung Naing

Showing results (221-230 of 397) with videos related to

Pageof 40
Sort By:
British Journal of Cancer|March 6, 2021
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignanciesShuyang Yao, Filip Janku, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trialAna M Gonzalez-Angulo, Funda Meric-Bernstam, Sant Chawla, et al.
Gynecologic Oncology Research and Practice|May 28, 2016
Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experienceSiqing Fu, Naiyi Shi, Jennifer Wheler, et al.
Molecular Cancer Therapeutics|December 15, 2017
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced CancersDivya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, et al.
Plos One|March 4, 2014
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitorsDenis L Jardim, Jennifer J Wheler, Kenneth Hess, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I studyAung Naing, John D Powderly, John J Nemunaitis, et al.
The American Journal of Cardiology|February 16, 2019
Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint InhibitorsNicolas Palaskas, Jacob Morgan, Tina Daigle, et al.
Investigational New Drugs|April 24, 2015
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapyHeloisa Veasey Rodrigues, Danxia Ke, JoAnn Lim, et al.
Scientific Reports|March 13, 2021
Associations between the gut microbiome and fatigue in cancer patientsJoud Hajjar, Tito Mendoza, Liangliang Zhang, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 15, 2024
Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLCDiego de Miguel-Perez, Murat Ak, Priyadarshini Mamindla, et al.
Pageof 40

Showing results (221-230 of 397) with videos related to

Sort By:
Pageof 40
British Journal of Cancer|March 6, 2021
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignanciesShuyang Yao, Filip Janku, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trialAna M Gonzalez-Angulo, Funda Meric-Bernstam, Sant Chawla, et al.
Gynecologic Oncology Research and Practice|May 28, 2016
Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experienceSiqing Fu, Naiyi Shi, Jennifer Wheler, et al.
Molecular Cancer Therapeutics|December 15, 2017
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced CancersDivya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, et al.
Plos One|March 4, 2014
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitorsDenis L Jardim, Jennifer J Wheler, Kenneth Hess, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I studyAung Naing, John D Powderly, John J Nemunaitis, et al.
The American Journal of Cardiology|February 16, 2019
Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint InhibitorsNicolas Palaskas, Jacob Morgan, Tina Daigle, et al.
Investigational New Drugs|April 24, 2015
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapyHeloisa Veasey Rodrigues, Danxia Ke, JoAnn Lim, et al.
Scientific Reports|March 13, 2021
Associations between the gut microbiome and fatigue in cancer patientsJoud Hajjar, Tito Mendoza, Liangliang Zhang, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 15, 2024
Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLCDiego de Miguel-Perez, Murat Ak, Priyadarshini Mamindla, et al.
Pageof 40